1. Home
  2. GPOR vs IMNM Comparison

GPOR vs IMNM Comparison

Compare GPOR & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gulfport Energy Corporation

GPOR

Gulfport Energy Corporation

HOLD

Current Price

$159.15

Market Cap

3.0B

Sector

Energy

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$25.13

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPOR
IMNM
Founded
1997
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medicinal Chemicals and Botanical Products
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.5B
IPO Year
1998
2020

Fundamental Metrics

Financial Performance
Metric
GPOR
IMNM
Price
$159.15
$25.13
Analyst Decision
Buy
Strong Buy
Analyst Count
11
10
Target Price
$233.33
$32.80
AVG Volume (30 Days)
311.6K
1.0M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
245.92
51.40
EPS
13.82
N/A
Revenue
$1,422,583,000.00
$6,941,000.00
Revenue This Year
$18.35
N/A
Revenue Next Year
$6.04
$1,127.34
P/E Ratio
$11.47
N/A
Revenue Growth
48.47
N/A
52 Week Low
$149.18
$8.67
52 Week High
$225.78
$27.65

Technical Indicators

Market Signals
Indicator
GPOR
IMNM
Relative Strength Index (RSI) 49.38 72.37
Support Level $149.18 $19.28
Resistance Level $162.64 $27.14
Average True Range (ATR) 4.58 1.06
MACD 0.79 0.25
Stochastic Oscillator 60.12 87.53

Price Performance

Historical Comparison
GPOR
IMNM

About GPOR Gulfport Energy Corporation

Gulfport Energy Corp is an independent natural gas-weighted exploration and production company focused on the exploration, acquisition, and production of natural gas, crude oil, and natural gas liquids, with assets located in the Appalachia and Anadarko basins in the United States. The principal properties of the company are located in eastern Ohio, targeting the Utica and Marcellus, and in central Oklahoma, targeting the SCOOP Woodford and Springer formations.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: